At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 32 enrolled
Drug / intervention
TAK-954drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Parallel Group Trial to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single Intravenous Dose of TAK-954
In Brief
A Phase 1 clinical trial evaluating TAK-954 for Renal Impairment and Healthy Volunteers. Completed, enrolled 32 participants across 4 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the effect of varying degrees of renal function on the PK of TAK-954 following single-dose IV administration and to investigate the impact of hemodialysis on the PK of single IV doses of TAK-954.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRenal Impairment, Healthy Volunteers
CountriesCzechia, Hungary
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedSep 2017
Enrollment StartNov 2017
Primary CompletionAug 2019
TodayJul 2026
First PostedSep 28, 2017
Enrollment StartNov 21, 2017
Primary CompletionAug 9, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 8.8 years ago
Interventions
TAK-954drug
TAK-954 intravenous infusion.